Search

Your search keyword '"Huizinga, T"' showing total 1,868 results
Start Over Author "Huizinga, T"
1,868 results on '"Huizinga, T"'

1. Induction of Cure in Early Arthritis (I CEA): study protocol for an investigator-initiated randomized single-blind clinical trial with open-label extension to compare three treatment strategies in patients with newly diagnosed undifferentiated arthritis

Author

Bergstra, S. A., van Ouwerkerk, L., Nevins, I. S., van der Pol, J. A., Helmich, G. S., Hest, I., van Veen, A., Bos, R., Goekoop-Ruiterman, Y. P. M., Vonkeman, H. E., Bijsterbosch, J., de Jong, P. H. P., Güler-Yüksel, M., Böhringer, S., Huizinga, T. W. J., and van Gaalen, F. A.

Published
2024
Full Text
View/download PDF

3. Rheumatoid Arthritis Rheumatoid Arthritis

Author

Deane, Kevin D., Aletaha, Daniel, Bathon, Joan M., Emery, Paul, Fragoulis, George E., Holers, V. Michael, Huizinga, T. W. J., Kolfenbach, Jason R., O’Dell, James R., Pearson, Duane W., Park, Elizabeth, Smolen, Josef, Tanaka, Yoshiya, Taylor, Peter C., van der Helm-van Mil, Annette, van Vollenhoven, Ronald F., St. Clair, E. William, and Stone, John H., editor

Published
2023
Full Text
View/download PDF

4. Systemic Lupus Erythematosus

Author

Petri, Michelle, Aringer, Martin, Ayoub, Isabelle, Almaani, Salem, Brunner, Hermine, Dall’Era, Maria, Jiang, Mengdi, Furie, Richard, Greco, Jessica, Goldblatt, Fiona, Huggins, Jennifer, Huizinga, T. W. J., Isenberg, David, Li, Nicholas L., Monahan, R. C., Parikh, Samir V., Pisetsky, David, Puravath, Abin P., Rovin, Brad, Wallace, Daniel, Zhang, Xuan, Zhao, Lidan, and Stone, John H., editor

Published
2023
Full Text
View/download PDF

5. OP0033 FIBROBLAST GENE, FKBP7 INDUCED BY Ca2+DEPENDENT ER STRESS ASSOCIATED WITH CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE; MULTI-CENTRE GWAS AND FUNCTIONAL STUDIES

Author

Maurits, M. P., primary, Cameron, A., additional, Jelinsky, S., additional, Blüml, S., additional, Abasolo, L., additional, Askling, J., additional, Barton, A., additional, Böhringer, S., additional, Cope, A., additional, De, S., additional, Emery, P., additional, Eyre, S., additional, Gaddi, V. P., additional, González-Álvaro, I., additional, Goodyear, C. S., additional, Hu, X., additional, Huizinga, T., additional, Johannesson, M., additional, Jurado-Zapata, S., additional, Klareskog, L., additional, Lendrem, D., additional, Martin, P., additional, Mc Innes, I. B., additional, Micheroli, R., additional, Morgan, A., additional, Morton, F., additional, Naamane, N., additional, Nagafuchi, Y., additional, Orozco, G., additional, Padyukov, L., additional, Paterson, C., additional, Pitzalis, C., additional, Plant, D., additional, Porter, D., additional, Reynard, L., additional, Rodriguez Rodriguez, L., additional, Sieghart, D., additional, Studenic, P., additional, Taylor, J., additional, Toes, R. E. M., additional, Van den Akker, E. B., additional, Van der Helm – van Mil, A. H. M., additional, Vaskimo, L., additional, Verstappen, S., additional, Westerlind, H., additional, Isaacs, J., additional, Lewis, M., additional, Pratt, A., additional, Ospelt, C., additional, Winkler, A., additional, Thomas, R., additional, and Knevel, R., additional

Published
2024
Full Text
View/download PDF

15. Changes in Physical Function using Three Methods of Scoring the Health Assessment Questionnaire in Established Active Rheumatoid Arthritis.

Author

Winchow, Lai Ling, Tikly, Mohammed, Musenge, Eustasius, Chopra, Arvind, Huizinga, T. W. J., Salomon-Escoto, Karen, Tavares-Costa, José, and Govind, Nimmisha

Abstract

Background: We investigated sensitivity to change of three scoring methods of the Health Assessment Questionnaire (HAQ) in relation to change in disease activity in patients with active rheumatoid arthritis (RA). Patients and Methods: Adult RA-patients with complete data in the Measurement of Efficacy of Treatment in the Era of Outcome in Rheumatology database with respect to the 20 HAQ questions and disease activity score with 28-joint count using the erythrocyte sedimentation rate (DAS28-ESR) for 2 visits, at least 6-12 months apart, and high disease activity (DAS28-ESR >5.1) at visit 1. Changes in HAQ scored by the (1) conventional method (HAQ-8), (2) HAQ-Tomlin method (HAQ-T), and (3) HAQ-20-item method (HAQ-20) were analyzed in relation to the European League Against Rheumatism (EULAR) RA response criteria, dichotomized to good/moderate and no response. Results: In 421 patients, mean standard deviation (SD) DAS28-ESR declined significantly (6.1 [0.8]-4.8 [1.6], P < 0.0001), over a mean period (SD) of 8.7 (1.9) months. Median HAQ scores improved by all three scoring methods, HAQ-8 (1.6-1.4); HAQ-T (1.2-0.7); and HAQ-20 (1.2-0.9) with similar effect sizes of 0.97, 0.96, and 0.95, respectively. The proportion who achieved a HAQ minimally clinically important improvement (MCII) of =0.22 was significantly higher in 47% of patients with EULAR good/moderate score compared to the no response patients (64% vs. 11%, P < 0.0001). Good/moderate EULAR response, higher baseline DAS28, and higher baseline HAQ (7.11, 1.55, and 1.06, respectively) were independent predictors of achieving a HAQ-MCII. Conclusion: Three HAQ scoring methods performed similarly in sensitivity to change with no advantage of alternative scoring methods compared to the conventional HAQ-8 method. A good/moderate EULAR response, despite long disease duration, was associated with a significant likelihood of achieving a HAQ-MCII. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. OP0162 PATTERNS OF CLINICAL JOINT INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS

Author

Heckert, S. L., primary, Hissink Muller, P. C. E., additional, Van den Berg, J. M., additional, Schonenberg-Meinema, D., additional, Van Suijlekom-Smit, L. W. A., additional, Van Rossum, M., additional, Koopman-Keemink, Y., additional, Ten Cate, R., additional, Brinkman, D. M. C., additional, Huizinga, T., additional, Allaart, C., additional, and Bergstra, S. A., additional

Published
2023
Full Text
View/download PDF

20. AB1602 CROSS COUNTRY DIFFERENCES IN B/TSDMARD PRESCRIPTION BEHAVIOR: ASSOCIATIONS BETWEEN SOCIOECONOMICS, REAL WORLD B/TSDMARD USE AND DISEASE OUTCOMES

Author

Nevins, I., primary, Courvoisier, D., additional, Finckh, A., additional, Fritsch-Stork, R., additional, Nordström, D., additional, Rodrigues, A. M., additional, Dinescu, Ș. C., additional, García Martos, Á., additional, Oztas, M., additional, Rotar, Z., additional, Solomon-Escoto, K., additional, Chopra, A., additional, Vega-Morales, D., additional, De Buck, P. D., additional, Choquette, D., additional, Conway, R., additional, Iannone, F., additional, Allaart, C., additional, Huizinga, T., additional, Lauper, K., additional, and Bergstra, S. A., additional

Published
2023
Full Text
View/download PDF

21. POS1052 RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE ACROSS CONTINENTS

Author

Heckert, S. L., primary, Maarseveen, T., additional, Marges, E. R., additional, Chopra, A., additional, Vega-Morales, D., additional, Du Toit, R., additional, Winchow, L. L., additional, Toro Gutierrez, C. E., additional, Knevel, R., additional, Van der Helm – van Mil, A., additional, Huizinga, T., additional, Allaart, C., additional, and Bergstra, S. A., additional

Published
2023
Full Text
View/download PDF

22. POS1263 SMOKING INFLUENCE ON AUTOANTIBODY PROFILE AND DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: AN EUSTAR DATABASE ANALYSIS

Author

Ciaffi, J., primary, Liem, S., additional, Wiland, P., additional, Atsumi, T., additional, Szücs, G., additional, Pellerito, R., additional, Balbir-Gurman, A., additional, Czirják, L., additional, Zanatta, E., additional, Koetter, I., additional, Shah, A., additional, Henes, J., additional, Matucci-Cerinic, M., additional, Airò, P., additional, Ursini, F., additional, Huizinga, T., additional, and De Vries-Bouwstra, J., additional

Published
2023
Full Text
View/download PDF

27. POS0630 ANTIDRUG ANTIBODIES ARE NEGATIVELY ASSOCIATED WITH RESPONSE TO BIOLOGICAL DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF THE ABIRISK STUDY

Author

Bitoun, S., primary, Hässler, S., additional, Ternant, D., additional, Szely, N., additional, Gleizes, A., additional, Hacein Bey, S., additional, Richez, C., additional, Soubrier, M., additional, Avouac, J., additional, Brocq, O., additional, Sellam, J., additional, De Vries, N., additional, Huizinga, T., additional, Jury, E., additional, Manson, J., additional, Mauri, C., additional, Matucci, A., additional, Mulleman, D., additional, Pallardy, M., additional, Bröet, P., additional, and Mariette, X., additional

Published
2023
Full Text
View/download PDF

28. OP0130 ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL

Author

Cope, A., primary, Jasenecova, M., additional, Vasconcelos, J., additional, Filer, A., additional, Raza, K., additional, Qureshi, S., additional, D’agostino, M. A., additional, Mcinnes, I., additional, Isaacs, J., additional, Pratt, A., additional, Fisher, B., additional, Buckley, C. D., additional, Emery, P., additional, Ho, P., additional, Buch, M. H., additional, Ciurtin, C., additional, Huizinga, T., additional, Van Schaardenburg, D., additional, Murphy, C., additional, and Prevost, T., additional

Published
2023
Full Text
View/download PDF

29. NT-proBNP and sRAGE levels in early rheumatoid arthritis

Author

UMC Utrecht Holding, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Regenerative Medicine and Stem Cells, Heslinga, M., Teunissen, C., Agca, R., van der Woude, D., Huizinga, T. W.J., van Laar, J., den Broeder, A., Lems, W., Nurmohamed, M., UMC Utrecht Holding, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Regenerative Medicine and Stem Cells, Heslinga, M., Teunissen, C., Agca, R., van der Woude, D., Huizinga, T. W.J., van Laar, J., den Broeder, A., Lems, W., and Nurmohamed, M.

Published
2023

30. NT-proBNP and sRAGE levels in early rheumatoid arthritis

Author

Heslinga, M., Teunissen, C., Agca, R., Woude, D. van der, Huizinga, T., Laar, J. van, Broeder, A. den, Lems, W., Nurmohamed, M., Heslinga, M., Teunissen, C., Agca, R., Woude, D. van der, Huizinga, T., Laar, J. van, Broeder, A. den, Lems, W., and Nurmohamed, M.

Abstract

Item does not contain fulltext, OBJECTIVE: Several biomarkers of cardiovascular function are found to be increased in rheumatoid arthritis (RA), with some suggesting a relationship with disease activity and improvement with adequate anti-rheumatic treatment. Promising biomarkers include N-terminal pro-brain natriuretic peptide (NT-proBNP) and the soluble receptor form of advanced glycation end-products (sRAGE). The objective of this study was to investigate associations between NT-proBNP and sRAGE levels and markers of inflammation and disease activity in early RA patients and their changes during (effective) anti-rheumatic treatment. METHOD: Data from 342 consecutive early RA patients participating in the 'Parelsnoer' cohort were used. At baseline and after 6 months' disease activity, NT-proBNP and sRAGE levels were assessed. RESULTS: After 6 months, NT-proBNP decreased from 83 pmol/L (mean) at baseline to 69 pmol/L at follow-up (p < 0.001), while sRAGE increased from 997 pg/mL to 1125 pg/mL (p < 0.001). A larger decrease in erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was associated with larger changes in NT-proBNP and sRAGE. For every point decrease in ESR, there was a 1.7-point decrease in NT-proBNP and a 2.2-point increase in sRAGE. For CRP, these values were 1.7 and 2.7, respectively (p < 0.001). CONCLUSION: Suppressing inflammation, independently of achieving remission, increases sRAGE levels and decreases NT-proBNP levels significantly. Whether this translates into a decrease in incident cardiovascular disease remains to be elucidated.

Published
2023

38. One year in review 2020: novelties in the treatment of rheumatoid arthritis

Author

Silvagni, E, Giollo, A, Sakellariou, G, Ughi, N, D'Amico, M, Scire, C, Huizinga, T, Silvagni E., Giollo A., Sakellariou G., Ughi N., D'Amico M. E., Scire C. A., Huizinga T. W. J., Silvagni, E, Giollo, A, Sakellariou, G, Ughi, N, D'Amico, M, Scire, C, Huizinga, T, Silvagni E., Giollo A., Sakellariou G., Ughi N., D'Amico M. E., Scire C. A., and Huizinga T. W. J.

Abstract

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.

Published
2020

39. Integrated Cryo-CMOS Temperature Sensors for Quantum Control ICs

Author

't Hart, P.A. (author), Huizinga, T. (author), Babaie, M. (author), Vladimirescu, A. (author), Sebastiano, F. (author), 't Hart, P.A. (author), Huizinga, T. (author), Babaie, M. (author), Vladimirescu, A. (author), and Sebastiano, F. (author)

Abstract

This work presents an experimental study of different components (resistors, diodes, transistors) in a standard 40-nm bulk CMOS process for their suitability as integrated cryogenic temperature sensors down to a temperature of 4.2K. It was found that most devices can be employed as sensors down to temperatures of approximately 50K, below which non-ideal effects such as non-linear behaviour and decreased sensitivity start to dominate. The Dynamic-Threshold MOS (DTMOS) was found to be a very promising candidate for its linearity, low forward-voltage-drop and sensitivity down to 8K. Moreover, as previous research indicated that cryogenic self-heating raises the local chip temperature to tens of Kelvins already at moderate power levels, the aforementioned sensing limitations at very low temperatures are expected to be of less importance in realistic applications. The results presented in this work contribute to the further integration of classical cryo-CMOS control electronics and qubits, towards a fully scalable quantum computer., Green Open Access added to TU Delft Institutional Repository 'You share, we take care!' - Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public., QCD/Sebastiano Lab, Electronics, Quantum Circuit Architectures and Technology

Published
2022
Full Text
View/download PDF

49. OP0091 EXPANSION OF MYELOPEROXIDASE (MPO)-SPECIFIC IgM B CELLS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS

Author

Wortel, C., primary, van de Wetering, R., additional, van Dooren, H., additional, Stork, E. M., additional, Bakker, A. M., additional, Brehler, A. S., additional, Kissel, T., additional, Reijm, S., additional, Stoeken-Rijsbergen, G., additional, van Schie, K., additional, Rutgers, A., additional, Trouw, L. A., additional, Huizinga, T., additional, Teng, Y. K. O., additional, van Kooten, C., additional, Heeringa, P., additional, Toes, R., additional, and Scherer, H. U., additional

Published
2022
Full Text
View/download PDF

50. POS0579 ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY

Author

Emery, P., primary, Fleischmann, R., additional, Wong, R., additional, Lozenski, K., additional, Tanaka, Y., additional, Bykerk, V., additional, Bingham, C., additional, Huizinga, T., additional, Citera, G., additional, Elbez, Y., additional, Perera, V., additional, Murthy, B., additional, Maxwell, K., additional, Passarell, J., additional, Hedrich, W., additional, and Williams, D., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results